BrayK.R., GaurP.K., StoneM.R., LeungJ.P.A monoclonal antibody that detects a tumor associated antigen in the sera of patients with colon cancer.Fed Proc1987; 46: 1059.
2.
KobayashiM., YamaguchiA., ImaiT. Basic and clinical studies of serum CA 195 antigen assay with “BL-CA 195” kit.Kaku Igaku1993; 30: 441–7.
BhargavaA.K., PetrelliN.J., KarnaA.Serum levels of cancer-associated antigen CA 195 in gastrointestinal cancers and its comparison with CA19.9.J Clin Lab Anal1989; 3: 370–7.
5.
BrayK.R., GaurP.K.Serum levels of cancer-associated antigen 195, a circulating marker for colon cancer, and its relationship to carcinoembryonic antigen.J Clin Lab Anal1988; 2: 187–93.
6.
DufekV., PetrylJ., KlenerP., ChmelJ.I.Tumor markers in the diagnosis of tumors in the subhepatic area.Vnitr Lek1994; 40: 350–3.
7.
GuptaM.K., ArciagaR., BukowskyR., GaurP.K.Ca 195: A new sensitive monoclonal antibody-defined tumor marker for pancreatic cancer.J Tumor Marker Oncol1987; 2: 201–6.
8.
HyotyM., HyotyH., AaranR.K., AiroI., NordbackI.Tumor antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.Eur J Surg1992; 158: 173–9.
9.
KornekG., DepischC.H., TemshC.H., ScheithauerW.Comparative analysis of cancer-associated antigen CA 195, CA 19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancer.J Cancer Res Clin Oncol1991; 117: 493–6.
10.
MaharajB., PillayS., PadayachiT.Circulating CA 195 in hepatocellular carcinoma and metastatic hepatic carcinoma.Trop Geogr Med1991; 43: 329–31.
11.
MassonP., PalssonB., Andren-SandbergA.Evaluation of CEA, CA 19-9, CA-50, CA 195, and TATI with special reference to pancreatic disorders.Int J Pancreatol1991; 8: 333–44.
12.
NicoliniA., CaciagliM., ZampieriF.Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colorectal cancer and at its relapse.Cancer Detect Prev1995; 19: 183–95.
13.
PiantinoP., FusaroA., RandoneA., CerchierA., DazianoE.Increased levels of CA 19.9, CA 50, and CA 195 in patients with benign disease of the biliary tract and the pancreas.J Nucl Med Allied Sci1990; 34: 97–102.
14.
RuggeriG., BelloliS., CasellaC.CA 195 as a tumor marker in patients with gastrointestinal cancer. In: BallestaA.M., TorreG.C., BombardieriE., GionM., MolinaR., eds. Updating on tumor markers in tissues and in biological fluids.Torino: Edizioni Minerva Medica1993; 545–53.
15.
SagarP.M., TaylorO.M., CooperE.H., BensonE.A., McMahonM.J., FinanP.J.The tumor marker CA 195 in colorectal and pancreatic cancer.Int J Biol Markers1991; 6: 241–6.
16.
SundaramS.G., ManimekalaiS., UnniS.Evaluation of antigen CA 195 for the detection of colon cancer.J Tumor Marker Oncol1987; 2: 315–8.
17.
TaylorO.M., CooperE.H., BensonE.A., McMahonM.J.The prognostic value of the tumor markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.Eur J Surg Oncol1992; 18: 508–13.
18.
VerdiC.J., AhmannF.R., SchifmanR.B., ElvickA.L., AhmannM.E., MarxP.C.Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.Cancer1993; 71: 3625–32.
19.
AndiocoecheaA., VizosoF., AlexandreE., RuibalA.Comportamiento del antígeno carbohidrato 195 (CA 195) en el suero de pacientes con patologías no tumorales.Med Clin (in press).
